# FEB 2 3 2010

# 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS SASTM FluAlert A Test

This ${ \mathfrak { s l o } } ( { \mathbf k } )$ summary of safety and effectiveness submission is in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Submitted by:

SA Scientific, Ltd. 4919 Golden Quail San Antonio, TX 78240 210-699-8800

# Establishment Reg. No:

1645225

Contact Person:

Robbi Perry

Date Prepared:

January 22, 2010

Proprietary Name:

SASTM FluAlert A Test

Classification Name:

Antigens, CF (including CF control), Influenza virus A, B, C

Device Classification:

21 CFR Part 866.3330

Regulatory Class:

Class I

Classification Advisory Committee:

Microbiology

Product Code:

GNX

Substantial Equivalence:

SASTM FluAlert A Test, manufactured by SA Scientific, Ltd., San Antonio, TX.

Device Description:

The SASTM FluAlert A Test utilizes antibodies against influenza type A viral nucleoproteins. The SASTM FluAlert A test begins with an extraction of Type A nucleoproteins. After the extraction has been completed, the sample is placed into the sample well of the test. The specimen is absorbed and migrates via capillary action through miembranes that contain dried gold conjugated antibody, which is specific for influenza A viral nucleoproteins. If these nucleoproteins are present, a "half-sandwich" immunocomplex is formed. The membrane contains immobilized antibody to influenza A nucleoproteins, which binds the "half sandwich" complex. Thus, in the presence of influenza A nucleoproteins, a "whole sandwich" immunocomplex is formed and a visible, pink-colored line develops in the specimen zone of the test device. In the absence of an influenza A antigen, a "sandwich" immunocomplex is not formed and a negative result is indicated. To serve as a procedural control, a pink-colored control line will always appear in the control zone of each strip regardless of the presence or absence of influenza A nucleoproteins.

Intended Use:

SASTM FluAlert A Test is a visual and rapid assay for the presumptive in-vitro qualitative detection of influenza A viral nucleoprotein antigens from nasal washes and nasal aspirates of symptomatic patients. Negative results should be confirmed via culture. This test is not intended for the detection of Influenza Type B or Influenza Type C viral antigen. This test is for professional use only.

Negative results do not preclude infection with influenza A and should not be used as the sole basis for treatment or other patient management decisions. It is recommended that negative results be confirmed by cell culture.

Conditions for Use:

For prescription use only.

Quality Controls:

The SASTM FluAlert A Test provides an internal procedural quality control. It is recommended that external quality controls be assayed following the user's laboratory's standard quality control procedures and in conformance with local, state and federal regulations or accreditation organizations as applicable

Device comparison:

The SASTM FluAlert A is a rapid immunoassays utilizing immunochromatographic technology for the visualization of influenza A antigen. Each utilizes an antibody conjugated to colored particles and an antibody printed onto a membrane.

Performance Summary:

This test has been shown to detect the FluA/Califoria/04/2009 (H1N1) virus cultured from a positive human specimen however, the performance characteristics of this test with clinical specimens that are positive for the 2009 H1N1 influenza virus have not been established. The SAS FluAlert A Test can detect influenza A virus, but cannot differentiate influenza subtypes.

Clinical Summary:

Please see K041441 for Clinical Summary

Note: Performance characteristics for detecting the 2009 H1N1 influenza vlrus from human specimens have not been established

Analytical Sensitivity (Limit of Detection):

The analytical sensitivity of the SASTM FluAlert A Test was determined for 2009 HIN1 using strain A/California/04/09. 2009 H1N1 using strain A/California/04/09. Each strain was serially diluted in SASTM FluAlert A extraction buffer. Results for A/California/04/09 are included in the summary table below.

<table><tr><td rowspan=1 colspan=1>InfluenzaViral Strain</td><td rowspan=1 colspan=1>ATCC</td><td rowspan=1 colspan=1>LoDTCIDsg/0.2 ml</td></tr><tr><td rowspan=1 colspan=1>H1N1 A/PR/3/34</td><td rowspan=1 colspan=1>.VR-95</td><td rowspan=1 colspan=1>1.2x 10^{}$</td></tr><tr><td rowspan=1 colspan=1>H3N2 A/Aichi/2/68</td><td rowspan=1 colspan=1>VR-547</td><td rowspan=1 colspan=1>5.6 x 10^2</td></tr><tr><td rowspan=1 colspan=1>H3N2 A/HongKong/8/6/8</td><td rowspan=1 colspan=1>VR-544</td><td rowspan=1 colspan=1>3.5 x 103</td></tr><tr><td rowspan=1 colspan=1>HIN1 A/FM/147</td><td rowspan=1 colspan=1>VR-97</td><td rowspan=1 colspan=1>7.9 x 10^3$</td></tr><tr><td rowspan=1 colspan=1>H3N2A/Victoria/3/75</td><td rowspan=1 colspan=1>VR-822</td><td rowspan=1 colspan=1>4.5 x.10</td></tr><tr><td rowspan=1 colspan=1>H1N1A/Califoria/04/09</td><td rowspan=1 colspan=1>NR-13658</td><td rowspan=1 colspan=1>1.4 x 103</td></tr></table>

\*This test has been shown to detect the FluA/Califoia/04/2009 (H1N1) virus cultured from a positive uman H1N1 influenza virus have not been established.The SAS FluAler A Test can detect influenza A viruses, but cannot differentiate influenza subtypes. C    ot

Conclusion:

The information presented in the premarket notification demonstrates that the SASTM FluAlert A Test reacts with a cultured strain of 2009 H1N1

(FluA/California/04/2009). Although this test has been shown to detect the 2009 H1N1 from a cultured isolate, the performance characteristics of this test with clinical specimens that are positive for the 2009 H1N1 influenza virus have not been established. The SAS FluAlert A Test can detect influenza A viruses, but cannot differentiate influenza subtypes. This viral strain used in this study was obtained from ATCC with a known titer. SA Scientific, Ltd did not verify this titer.

# Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center-WO66-G609 Silver Spring, MD 20993-0002

FEB 2 3 2010

SA Scientific, Inc.   
c/o Ms. Robbi Perry MT (ASCP) Regulatory Affairs Specialist   
4919 Golden Quail   
San Antonio, Texas 78240

Re: k100227 Trade/Device Name: SAS FluAlert A Test Regulation Number: 21 CFR 866.3330 Regulation Name: Influenza Virus Serological Reagents Regulatory Class: Class I Product Code: GNX Dated: February 23, 2010 Received: January 26, 2010

Dear Ms. Perry:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices markete ininterstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

yrvieovicas los A be subject to such additional controls. Existing major regulations affecting your device can be fd in Tite 1, Code ofFederal Regulations (CFR) Parts 800 to 89.In adition, FDAy publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with allthe Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.   
You may obtain other general information on your responsibilities under the Act from the   
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number   
(800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

![](images/75e481d42ab6b63067924b8d9a6eaf81c5a77595b881797a6fa83584e6dd9991.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): k100227

Device Name: SAST FluAlert A Test

Indication For Use:

SASâ„¢m FluAlert A Test is a visual and rapid assay for the presumptive in-vitro qualitative detection of Influenza A viral nucleoprotein antigens from nasal washes and nasal aspirates of symptomatic patients. The test is not intended for the detection of Influenza Type B viral antigen or Influenza Type C viral antigen. This test is for professional use only.

Negative results do not preclude infection with influenza A and should not be used as the sole basis for treatment or other patient management decisions. It is recommended that negative results be confirmed by cell culture.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

![](images/66ad843dc25476500b5948edb721ae957b3b4a98e885d7028344b76373a2b66b.jpg)

Office of In Vitro Diagnostic Device Evaluation and Safety